Received Feb 11, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MEN | MENINGOCOCCAL (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | U8574A A | — |
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | UNK | — |
wrong vaccine administered; Drug dose administration interval too long; This non-serious case was reported by a other health professional via other manufacturer and described the occurrence of wrong vaccine administered in a 17-year-old female patient who received Men B NVS (Bexsero) for prophylaxis. Co-suspect products included Men B NVS (Bexsero) for prophylaxis and Meningococcal vaccine A/C/Y/W conj (tet tox) (Menquadfi) (batch number U8574A A) for prophylaxis. Previously administered products included Bexsero (Patient received first dose of Bexsero on 19-AUG-2019). On 11-DEC-2024, the patient received the 2nd dose of Bexsero. The patient did not receive the 3rd dose of Bexsero. On 18-NOV-2025, the patient received Menquadfi. On 11-DEC-2024, an unknown time after receiving Bexsero, the patient experienced drug dose administration interval too long (Verbatim: Drug dose administration interval too long). On an unknown date, the patient experienced wrong vaccine administered (Verbatim: wrong vaccine administered). The outcome of the wrong vaccine administered and drug dose administration interval too long were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 02-JAN-2026 The reporter reported that the patient was supposed to get Bexsero but was given Menquadfi instead with no reported adverse event. The batch number was not provided and a request for this information has been made. Upon internal review on 02-FEB-2026 The additional suspect product added with drug not administered tick box updated. Onset date for drug dose administration interval too long was updated.